Navigation Links
Dual treatment for stroke leads to improved recovery rates, reduced mortality

MINNAPOLIS / ST. PAUL (Nov. 12, 2008) It appears that stroke patients who receive both intravenous thrombolysis a minimally invasive treatment that dissolves abnormal blood clots and endovascular interventions such as drugs and implanting medical devices are much more likely to recover and have lower chances of dying, according to new research by the Zeenat Qureshi Stroke Research Center at the University of Minnesota Medical School.

Between 2003 and 2006, 33 consecutive patients with acute ischemic stroke which occurs when a blood clot blocks an artery in the brain were treated with thrombolysis in combination with endovascular interventions, which includes low doses of clot-fighting drugs and medical procedures such as angioplasty. The study looked at the outcomes of consecutive patients from a tertiary stroke facility where endovascular treatment was routinely available for patients treated with intravenous thromboysis. Outcomes were compared with a control cohort of 30 consecutive patients treated with thrombolysis at a comparable facility where endovascular interventions were not available.

Researchers found that the group that received both therapies experienced significantly lower mortality at 90 days (about 12 percent compared with 40 percent) with a significantly greater improvement in neurological ability by the time of discharge or follow-up. Patients younger than 80 years old showed the greatest improvement, with significant improvement in neurological deficits prior to treatment at the time of stroke.

The results were published in a recent issue of the American Journal of Neuroradiology.

"In theory it made sense to administer both treatments, but this is the first time we have the data to support the therapeutic benefit of such an approach," said Adnan I. Qureshi, M.D., executive director of the Stoke Initiative and Center at the University of Minnesota. "This is objective data to support the benefit of combination of intravenous thrombolysis and endovascular treatments."

Since the introduction of thrombolysis in the mid-1990s to clinical practice, no other treatment has been proved to further improve the clinical outcomes in patients with ischemic stroke which is why this study is important, Qureshi said.

Since both thrombolysis and additional endovascular treatments are not available at all medical centers, Qureshi said the bigger implications of this study support the creation of specialized stroke centers or designated stoke hospitals for patients who have suffered a stoke so they can receive better care.


Contact: Nick Hanson
University of Minnesota

Related medicine news :

1. Idea to Arm Cancer Patients with Information Specific to Their Disease and Treatment Receives Nod, Grant from American Cancer Society
2. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
3. Dental Implants Effective for Orthodontic Treatment
4. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
5. Bone cancer treatment ineffective, despite promising laboratory data
6. Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
7. Researchers find predictive tests and early treatment delay progression of blood cell cancer
8. New Treatment Options for Seasonal Affective Disorder, from Harvard Mental Health Letter
9. Game Ready(TM) Announces New Hand Treatment
10. Northwestern Medical Faculty Foundation Signs Long-Term Agreement to be the Provider of Doctors for Northern Illinois Proton Treatment and Research Center
11. How women can improve their quality of life after breast cancer treatment
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: